28.41

7.59% 2.005

Arcutis Biotherapeutics Inc (ARQT)

Overview News Price History Option Chain Financials Discussions Forecast

Arcutis Biotherapeutics Inc stock is traded at $28.41, with a volume of 1.89M. It is up +7.59% in the last 24 hours and up +20.86% over the past month. Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Previous Close:

$26.41

Open:

$26.93

24h Volume:

1.89M

Relative Volume:

0.97

Market Cap:

$3.57B

Revenue:

$415.62M

Net Income/Loss:

$-2.38M

P/E Ratio:

-1,000.53

EPS:

-0.0284

Net Cash Flow:

$16.92M

1W Performance:

+16.03%

1M Performance:

+20.86%

6M Performance:

+15.60%

1Y Performance:

+31.37%

1-Day Range:

$26.93

$28.96

1-Week Range:

$24.30

$26.97

52-Week Range:

$19.30

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name

Arcutis Biotherapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

805-418-5006

Address

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Employee

354

Twitter

@ArcutisBio

Next Earnings Date

2026-10-27

Latest SEC Filings

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARQT Arcutis Biotherapeutics Inc	28.41	3.57B	415.62M	-2.38M	16.92M	-0.0284
VRTX Vertex Pharmaceuticals Inc	509.72	129.19B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.78	94.93B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.11	82.48B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.35	53.35B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.37	42.01B	5.76B	514.49M	1.10B	4.4813

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Initiated	Goldman	Neutral
Dec-30-24	Initiated	H.C. Wainwright	Buy
Aug-28-24	Initiated	Jefferies	Buy
Jan-03-24	Upgrade	Mizuho	Neutral → Buy
Oct-26-23	Downgrade	Mizuho	Buy → Neutral
Oct-13-23	Downgrade	Goldman	Buy → Neutral
Sep-07-22	Initiated	Needham	Buy
Mar-17-22	Initiated	Goldman	Buy
Jun-30-21	Initiated	Mizuho	Buy
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-09-20	Upgrade	Goldman	Neutral → Buy
Oct-08-20	Initiated	Truist	Buy
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight
Feb-25-20	Initiated	Cowen	Outperform
Feb-25-20	Initiated	Goldman	Neutral
Feb-25-20	Initiated	Guggenheim	Buy

View All

Arcutis Biotherapeutics Inc Stock (ARQT) Latest News

Oct 09, 2026

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - GlobeNewswire Inc.

Oct 09, 2026

Oct 05, 2026

An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake. - Stock Titan

Oct 05, 2026

Oct 02, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 02, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Oct 02, 2026